Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - nature.com
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …
被引用次数：72 相关文章

[引用][C] Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - cir.nii.ac.jp
Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell
transplantation is a predictor of relapse and survival | CiNii Research CiNii 国立情報学研究所 …

[引用][C] Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R LAMBA, E ABELLA, D KUKURUGA, J KLEIN… - …, 2004 - pascal-francis.inist.fr
Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell
transplantation is a predictor of relapse and survival CNRS Inist Pascal-Francis CNRS …

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival.

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - europepmc.org
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival.

R Lamba, E Abella, D Kukuruga, J Klein… - Leukemia …, 2004 - search.ebscohost.com
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …
[PDF] academia.edu

[PDF][PDF] Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - academia.edu
Allogenic stem cell transplantation is performed with a curative intent in various malignant
hematological disorders. Despite the use of various types of conditioning regimens …

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein… - …, 2004 - pubmed.ncbi.nlm.nih.gov
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - go.gale.com
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …
[PDF] researchgate.net

[PDF][PDF] Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

R Lamba, E Abella, D Kukuruga, J Klein, S Savasan… - Leukemia, 2004 - researchgate.net
Allogenic stem cell transplantation is performed with a curative intent in various malignant
hematological disorders. Despite the use of various types of conditioning regimens …

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival.

R Lamba, E Abella, D Kukuruga, J Klein… - Leukemia …, 2004 - search.ebscohost.com
We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …